MicroMedicine announced that it has appointed Dr. Marcela Maus to its Scientific Advisory Board.
“I am very excited to join MicroMedicine’s Advisory Board and offer insights that may help to further develop novel cell isolation technologies. The fields of cell therapy and regenerative medicine are in urgent need of a bioengineering-driven approach to the manufacturing process, starting with efficient and less manipulative methods for cell handling and extraction,” Maus said in a press release. “The development of gentler and more precise technology shows great promise to assist researchers and therapy developers in meeting their goals.”
Maus is an oncologist and director of cellular immunotherapy at Massachusetts General Hospital Cancer Center. She is also a member of the Center for Cancer Immunology and the Department of Medicine at Massachusetts General Hospital. Her lab focuses on creating next-generation CAR-T cells.
“Dr. Maus’s expertise and guidance will accelerate the advancement of our microfluidic platform technology to address the key challenges in cell therapy manufacturing and regenerative medicine. We are thrilled to have her on our advisory board and consider it further validation of our focus and applications in this space,” cofounder and CEO of MicroMedicine Dr. Ravi Kapur said.
